DuoCAR20.19.22-D95 / University of Kansas Medical Center - LARVOL DELTA

Point-of-care manufacturing and early clinical evaluation of a tri-specific (CD19/20/22) CAR T-cell therapy for relapsed or refractory (R/R) B-cell malignancies (AACR 2026) - "Patients receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single intravenous infusion of DuoCAR20.19.22-D95. These early data demonstrate the feasibility of point-of-care manufacturing, a favorable safety profile, and preliminary antitumor activity of a first-in-human, investigator-initiated tri-specific CD19/20/22 CAR T-cell therapy, supporting further dose escalation and expansion."

CAR T-Cell Therapy • Clinical • First-in-human • Trispecific • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22 • ICOS

Flow Cytometry-Based Lower Limit of Quantitation (LLOQ) Validation for Detection of DuoCAR20.19.22-D95 CAR T Cells in Support of a Phase 1/2 Clinical Trial for B-cell Malignancies (SITC 2025) - "The established LLOQ supports downstream pharmacokinetic, pharmacodynamic, and MRD assessments in the ongoing clinical trial. This assay enables sensitive monitoring of cellular kinetics, contributing to the overall evaluation of therapeutic safety and efficacy."

CAR T-Cell Therapy • Clinical • P1/2 data • Hematological Malignancies • Oncology • CD22 • CD8 • PTPRC

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: University of Kansas Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients with Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - P1 | N=54 | Not yet recruiting | Sponsor: University of Kansas Medical Center

New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology